Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

SELL
$0.42 - $0.72 $4,947 - $8,480
-11,779 Reduced 9.07%
118,098 $74,000
Q3 2023

Nov 13, 2023

SELL
$0.6 - $1.53 $363,620 - $927,232
-606,034 Reduced 82.35%
129,877 $77,000
Q2 2023

Aug 15, 2023

BUY
$1.05 - $1.63 $114,259 - $177,374
108,819 Added 17.35%
735,911 $831,000
Q1 2023

May 12, 2023

BUY
$1.2 - $2.73 $638,902 - $1.45 Million
532,419 Added 562.38%
627,092 $846,000
Q4 2022

Feb 13, 2023

BUY
$1.71 - $3.61 $28,560 - $60,294
16,702 Added 21.42%
94,673 $176,000
Q3 2022

Nov 14, 2022

SELL
$1.9 - $8.63 $4,816 - $21,877
-2,535 Reduced 3.15%
77,971 $192,000
Q2 2022

Aug 12, 2022

SELL
$2.13 - $9.01 $145,981 - $617,509
-68,536 Reduced 45.98%
80,506 $197,000
Q1 2022

May 16, 2022

SELL
$6.28 - $15.59 $476,055 - $1.18 Million
-75,805 Reduced 33.71%
149,042 $1.19 Million
Q4 2021

Feb 14, 2022

SELL
$14.7 - $28.67 $273,522 - $533,462
-18,607 Reduced 7.64%
224,847 $3.43 Million
Q3 2021

Nov 15, 2021

SELL
$24.31 - $33.6 $721,545 - $997,281
-29,681 Reduced 10.87%
243,454 $6.92 Million
Q2 2021

Aug 16, 2021

SELL
$26.09 - $40.4 $9.3 Million - $14.4 Million
-356,306 Reduced 56.61%
273,135 $9.21 Million
Q1 2021

May 13, 2021

SELL
$33.06 - $56.93 $5.68 Million - $9.78 Million
-171,862 Reduced 21.45%
629,441 $24.1 Million
Q4 2020

Feb 09, 2021

SELL
$39.09 - $57.4 $11.6 Million - $17 Million
-296,118 Reduced 26.98%
801,303 $33.5 Million
Q3 2020

Nov 05, 2020

BUY
$28.43 - $44.67 $10.3 Million - $16.1 Million
361,167 Added 49.05%
1,097,421 $47.6 Million
Q2 2020

Aug 13, 2020

SELL
$11.71 - $30.29 $269,060 - $695,973
-22,977 Reduced 3.03%
736,254 $22.3 Million
Q1 2020

May 14, 2020

BUY
$7.64 - $27.5 $5.8 Million - $20.9 Million
759,231 New
759,231 $10.4 Million

Others Institutions Holding NVTA

About Invitae Corp


  • Ticker NVTA
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 235,266,000
  • Description
  • Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...
More about NVTA
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.